Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Immunomodulators for Steroid-Dependent Recurrent Acute Pancreatitis After Immune Checkpoint Inhibitor Therapy: A Case Series. ACG Case Rep J 2025 Apr;12(4):e01653

Date

04/04/2025

Pubmed ID

40182191

Pubmed Central ID

PMC11968019

DOI

10.14309/crj.0000000000001653

Abstract

One to 2% of patients undergoing immune checkpoint inhibitor (ICI) therapy develop ICI-induced pancreatitis (ICI-IP). A small subset of these patients develop recurrent pancreatitis, even after discontinuation of ICI therapy. This case series presents 2 patients with recurrent steroid-responsive ICI-IP who were managed with immunomodulators as steroid-sparing agents. Both patients were maintained on immunomodulators for approximately 2 years before discontinuation of the agents, with no further recurrence or complications of pancreatitis. This case series highlights the use of mycophenolate mofetil and azathioprine for the management of recurrent ICI-IP.

Author List

Peck H, Pagani W, Smith A, Madhavan S

Authors

Srivats Madhavan MBBS Assistant Professor in the Medicine department at Medical College of Wisconsin
Arianna Smith DO Instructor in the Medicine department at Medical College of Wisconsin